Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

@article{Swedberg2010IvabradineAO,
  title={Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study},
  author={Karl Swedberg and Michel Komajda and Michael B{\"o}hm and Jeffrey S. Borer and Ian Ford and Ariane Dubost-Brama and Guy Lerebours and Luigi Tavazzi},
  journal={The Lancet},
  year={2010},
  volume={376},
  pages={875-885}
}

Figures and Tables from this paper

Ivabradine tolerability in heart failure
TLDR
The main results showed significant improvements in Health-Related Quality of Life (HRQoL) and functional status with ivabradine following 6 months of treatment (primary end point) and the longterm use and tolerability of ivABradine from the LIVE: LIFE study.
Limited role for ivabradine in the treatment of chronic heart failure
TLDR
The proportion of patients attending a community heart failure clinic with left ventricular systolic impairment who might be suitable for ivabradine therapy fell from 19.4% at baseline to 14.1% at 4 months and finally 9% by the 12-month clinic visit.
Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study
TLDR
Treatment with ivabradine, on a background of guidelines-based HF therapy, is associated with a substantial reduction in the likelihood of recurrent hospitalizations for worsening HF, which can be expected to improve the quality of life and to substantially reduce health-care costs.
Ivabradine: Heart Failure and Beyond.
TLDR
This trial assessed patients with stable heart failure with reduced ejection fraction and a heart rate of at least 70 beats per minute at rest on maximally tolerated beta-blocker therapy and demonstrated statistically significant reduction in heart failure hospitalization and deaths.
Ivabradine in stable coronary artery disease without clinical heart failure.
TLDR
Among patients who had stable coronary artery disease without clinical heart failure, the addition of ivabradine to standard background therapy to reduce the heart rate did not improve outcomes and was associated with an increase in the incidence of the primary end point among patients with activity-limiting angina but not among those without activity- Limiting Angina.
Cost-Effectiveness of Ivabradine in the Treatment of Chronic Heart Failure.
Efficacy Profile of Ivabradine in Patients with Heart Failure plus Angina Pectoris
TLDR
In SHIFT, ivabradine showed consistent reduction of cardiovascular outcomes in patients with CHF; similar results were seen in the subgroup of SHIFT patients with angina.
The SHIFT Study: The Role of Ivabradine in the Treatment of Heart Failure and Its Relevance in Clinical Practice
TLDR
It was found that the addition of ivabradine resulted in a reduction in the combined endpoint of cardiovascular death or readmission for heart failure, which was mainly due to a reduced in hospitalization for exacerbations of congestive symptoms.
Ivabradine: the start of a SHIFT in heart failure treatment
TLDR
Ivabradine is a selective inhibitor of the If ion channel found in cardiac pacemaker cells of the sinoatrial node, which reduces heart rate at rest and during exercise in patients in sinus rhythm while maintaining myocardial contractility and atrioventricular conduction.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 31 REFERENCES
Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial
TLDR
Multivariate analysis of CIBIS II showed that in addition to β-blocker treatment, B HR and HRC were both significantly related to survival and hospitalization for worsening HF, with the lowest BHR and the greatest HRC being associated with best survival and reduction of hospital admissions.
Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study
TLDR
In euvolemic patients with symptoms at rest or on minimal exertion, the addition of carvedilol to conventional therapy ameliorates the severity of heart failure and reduces the risk of clinical deterioration, hospitalization, and other serious adverse clinical events.
Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial
TLDR
B HR and HRC are significantly related to prognosis in heart failure and bisoprolol-induced benefit over placebo for survival was observed to a similar extent at any level of both BHR and HRC.
Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure.
TLDR
The magnitude of heart rate reduction is statistically significantly associated with the survival benefit of beta-blockers in heart failure, whereas the dose ofBeta-blocker is not, and heterogeneity testing revealed moderate heterogeneity among trials.
...
1
2
3
4
...